EXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel Today

Novo Nordisk's IDegLira, which is a combination of an ultralong acting basal insulin analogue Insulin degludec and glucagonlike peptide 1 agonist Liraglutide, for the treatment of type 2 diabetes, is all set to be reviewed by an FDA advisory panel on May 24, 2016.

from RTT - Biotech http://ift.tt/1TIq8fH
via IFTTT